Orchid is a reproductive technology company offering the world's first whole genome report for embryos during IVF. The test can identify birth defects, neurodevelopmental disorders, chromosomal abnormalities, and pediatric and adult-onset cancers before a pregnancy begins.

Orchid's 30x whole genome reports sequence over 99% of an embryo's genome (compared to existing options that sequence less than 1%), using the same 4-6 cells required for traditional embryo screening. The platform screens for variants linked to more than 1,200 monogenic disorders and assesses polygenic disease risks.